HARP Panoramica delle azioni
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States.
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 1/6 |
| Crescita futura | 2/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 5/6 |
| Dividendi | 0/6 |
Harpoon Therapeutics, Inc. Concorrenti
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$23.01 |
| Massimo di 52 settimane | US$23.21 |
| Minimo di 52 settimane | US$3.11 |
| Beta | 2.1 |
| 1Variazione di 1 mese | 2.49% |
| Variazione a 3 mesi | 162.97% |
| Variazione di 1 anno | 243.43% |
| 3Variazione a 3 anni | -88.71% |
| Variazione a 5 anni | -81.26% |
| Variazione dall'IPO | -82.96% |
Notizie e aggiornamenti recenti
Recent updates
Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified
Jan 30
Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough
Oct 01Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts
Aug 14Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically
May 28Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely
Mar 11Harpoon Therapeutics appoints Luke Walker as CMO
Oct 04Harpoon Therapeutics: A Well Undervalued Tri-Specific Oncology Player
Sep 01Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation
Jul 30Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio
Jul 07Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?
Mar 08We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate
Nov 30Harpoon Therapeutics: A First Look
Sep 16Harpoon shares slide after early-stage prostate cancer study data fails to impress
Jun 04Rendimenti per gli azionisti
| HARP | US Biotechs | US Mercato | |
|---|---|---|---|
| 7D | 0.2% | -0.7% | -1.6% |
| 1Y | 243.4% | 19.8% | 30.8% |
Ritorno vs Industria: HARP exceeded the US Biotechs industry which returned 16% over the past year.
Rendimento vs Mercato: HARP exceeded the US Market which returned 31% over the past year.
Volatilità dei prezzi
| HARP volatility | |
|---|---|
| HARP Average Weekly Movement | 32.6% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Prezzo delle azioni stabile: HARP's share price has been volatile over the past 3 months.
Volatilità nel tempo: HARP's weekly volatility has increased from 21% to 33% over the past year.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2015 | 53 | Julie Eastland | www.harpoontx.com |
Harpoon Therapeutics, Inc. Riepilogo dei fondamenti
| HARP statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$492.35m |
| Guadagni(TTM) | -US$30.50m |
| Ricavi(TTM) | US$37.34m |
13.2x
Rapporto P/S-16.1x
Rapporto P/EHARP è sopravvalutato?
Vedi Fair Value e analisi di valutazioneGuadagni e ricavi
| HARP Conto economico (TTM) | |
|---|---|
| Ricavi | US$37.34m |
| Costo del fatturato | US$58.63m |
| Profitto lordo | -US$21.29m |
| Altre spese | US$9.21m |
| Guadagni | -US$30.50m |
Ultimi guadagni dichiarati
Sep 30, 2023
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -1.43 |
| Margine lordo | -57.02% |
| Margine di profitto netto | -81.67% |
| Rapporto debito/patrimonio netto | 194.4% |
Come si è comportato HARP nel lungo periodo?
Vedi performance storica e confronto